(Nasdaq: ALT), a clinical-stage biopharmaceutical company ... of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop ...

Further, a metabolic panel consisting of 21 metabolites was constructed and identified for GC diagnosis with AUCs of 0.921–0.971 and 0.907–0.940 in the discovery and verification dataset, respectively ...

Metabolic syndrome is a constellation of conditions that together increase the risk of type 2 diabetes, stroke, and cardiovascular problems, including heart attack. The features of metabolic syndrome ...

In patient-derived and animal tumour models, mubritinib suppressed glioblastoma stem cells and tumour growth by targeting ...

particularly in patients with metabolic risk factor. The objective of the current study was to create a new panel of biomarkers known as SteatoTest (ST) with sufficient predictive values for the ...

Alt.Latino The global Latinx community is evolving and growing fast.Alt.Latino is here to celebrate it and all of its nuances through music. Each episode, NPR Music's Felix Contreras and Anamaria ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Pemvidutide (ALT-801) is under development for the treatment of ...

AltTab brings the power of Windows alt-tab to macOS ...

NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities ...